
Greenpeace hails Italy court ruling allowing climate lawsuit against energy company ENI to go ahead
In an ordinance released on Monday, the Court of Cassation rejected ENI's motions to dismiss the lawsuit on jurisdictional grounds and ordered the case to be heard on its merits by a Rome tribunal.
ENI, for its part, said that it was greatly satisfied with the decision, and it expected that the Rome court would ultimately 'dismantle' the climate activists' claims of responsibility.
Greenpeace, environmental group ReCommon and a dozen Italian citizens had sued ENI and its two main government shareholders, the Italian finance ministry and development bank, in 2023 seeking damages for what they said were the effects of climate change.
The plaintiffs cited their fundamental rights enshrined in the European Convention of Human Rights, as well as Italy's ratification of various international climate accords and ENI's stated commitment to reaching climate reduction targets.
ENI and the government sought to dismiss the suit on jurisdictional and other grounds, but the Cassation court ruled that the case could go ahead.
For more than a century, scientists have known that large quantities of greenhouse gases, released from the burning of fossil fuels, go up into the atmosphere and heat the planet, leading to higher temperatures, rising sea levels and extreme weather events that are both more frequent and more intense.
Around the world in recent years, individuals, climate activist groups and local governments have sued energy companies and governments to try to force them to take concrete action to curb greenhouse gas emissions and compensate for losses associated with climate change.
Greenpeace and ReCommon called the ruling historic, saying it would impact current and future climate-related litigation in Italy. They say it brings Italian courts in line with other European countries that have recognized the rights of people to try to hold fossil fuel companies accountable for global warming through lawsuits, and called the ruling itself one of the most significant in climate change litigation internationally.
'No one, not even a colossus like ENI, can escape its responsibilities anymore,' the two groups said in a statement. 'Judges will finally be able to examine the merits of our case: those who pollute and contribute to the climate crisis must answer for their actions.'
ENI said that it welcomed the ruling.
'The proceedings can finally resume before the Court of Rome, where the unfounded theories put forward by Greenpeace and ReCommon regarding the alleged responsibility of Eni for climate change-related damages will be dismantled, in a context that is rigorous and respectful of the law, rather than driven by the instrumental, unfounded, and often misleading slogans of the two associations,' ENI said in a statement.
While the ruling doesn't enter into the merits of the case, Greenpeace and Recommon highlighted the judges' determination that Italian courts can have jurisdiction over claims about emissions by ENI subsidiaries in foreign countries, since in this case, harm allegedly occurred in Italy and decisions were made by the Italy-based parent company.
---
Nicole Winfield, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
39 minutes ago
- CTV News
Zelenskyy faces backlash as Ukrainians protest new anti-corruption law
A woman holds a phone with a sign reads "Veto" during the protest against the law aimed towards regulations of anti-corruption institutions in central Kyiv, Ukraine, Tuesday, July 22, 2025. (AP Photo/Alex Babenko) KYIV, Ukraine — Ukrainian activists called for more protests against a law they say weakens the country's anti-corruption bodies. The legislation has also drawn rebukes from European Union officials and international rights groups. Thousands of people gathered in the capital and other cities across Ukraine on Tuesday evening to urge President Volodymyr Zelenskyy to veto a controversial bill passed by Ukraine's Parliament earlier that day. After Zelenskyy approved it, activists called on social media for another demonstration in the center of Kyiv at 8 p.m. Wednesday. The legislation tightens government oversight of two key anti-corruption agencies. Critics say the step could significantly weaken the independence of those agencies and grant Zelenskyy's circle greater influence over investigations. Fighting entrenched corruption is crucial for Ukraine's aspirations to join the EU and maintain access to billions of dollars in Western aid in its fight against Russia's three-year invasion. Instead of vetoing the bill as protestors demanded, Zelenskyy signed it into law and argued for it, in a move that risked his public support after more than three years of war with Russia. Zelenskyy said the measure clears out 'Russian influence' from the fight against corruption and ensures punishment for those found guilty of it, after what he said were yearslong delays in criminal proceedings involving huge amounts of money. 'This is what Ukraine really needs,' Zelenskyy said in a Telegram post after midnight Wednesday. 'The cases that have been lying dormant must be investigated.' 'For years, officials who have fled Ukraine have been casually living abroad for some reason – in very nice countries and without legal consequences – and this is not normal,' he said. He didn't provide examples of what he said was Russian interference. Russian officials relished Zelenskyy's difficulties. Russian Foreign Ministry spokesperson Maria Zakharova mocked Zelenskyy's claim of Russian infiltration into the anti-corruption agency, noting sarcastically that 'they might just as well pull a couple of bears out of the corner.' Zelenskyy has been the international face of Ukraine's determination to defeat Russia's all-out invasion, and his domestic troubles are an unwelcome diversion from the war effort. Delegations from Russia and Ukraine were set to meet in Istanbul on Wednesday for their third round of direct talks in two months, although the Kremlin didn't confirm the date or venue and its spokesman warned against expecting 'any magical breakthroughs' in the meeting. The changes would grant the prosecutor general new authority over investigations and cases handled by the National Anti-Corruption Bureau of Ukraine (NABU) and the Specialized Anti-Corruption Prosecutor's Office (SAPO). In a post on X, the EU's Enlargement Commissioner Marta Kos expressed concern over the vote in the Ukrainian Parliament, called the Rada, calling it 'a serious step back.' The Ukrainian branch of Transparency International criticized Parliament's decision, saying it undermines one of the most significant reforms since what Ukraine calls its Revolution of Dignity in 2014, and damages trust with international partners. It accused authorities of 'dismantling' the country's anti-corruption architecture. The mood of anger and frustration among the war-weary Ukrainians prevailed in the crowd Tuesday. Some protesters accused Ukraine's leadership of prioritizing loyalty and personal connections over the fight against corruption. 'Those who swore to protect the laws and the Constitution have instead chosen to shield their inner circle, even at the expense of Ukrainian democracy,' said veteran Oleh Symoroz, sitting in a wheelchair because both his legs were amputated after he was wounded in 2022. ___ Illia Novikov, The Associated Press


Globe and Mail
an hour ago
- Globe and Mail
DOW Gears Up for Q2 Earnings: What's in the Cards for the Stock?
Dow Inc. DOW is scheduled to come up with second-quarter 2025 results before the opening bell on July 24. DOW surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed twice. It has a trailing four-quarter earnings surprise of 24.2% on average. Dow posted an earnings surprise of 200% in the last reported quarter. While DOW is expected to have benefited from its productivity initiatives, soft demand due to weak global economic activities and pricing pressures are likely to have affected its second-quarter performance. Dow's shares are down 44.4% over a year compared with the Zacks Chemicals Diversified industry's 18.4% decline. Let's see how things are shaping up for this announcement. What Do DOW's Revenue Estimates Say? The Zacks Consensus Estimate for revenues for DOW for the to-be-reported quarter is pinned at $10,445.6 million, suggesting a year-over-year decline of 4.6%. Our estimate for revenues for the Packaging & Specialty Plastics segment is currently pegged at $5,197.9 million, calling for a decline of 5.8% year over year. The same for the Industrial Intermediates & Infrastructure segment stands at $2,884.6 million, indicating a 2.3% year-over-year decline. Our estimate for revenues for the Performance Materials & Coatings segment is pinned at $2,142.1 million, suggesting a fall of 4.5% year over year. Factors Shaping DOW's Q2 Results Dow is expected to have faced headwinds from demand softness in Europe and China in the quarter to be reported. Lower consumer spending amid inflationary pressures is affecting demand in Europe. Construction and manufacturing activities remain soft in the region. Demand in Asia has been affected by a weaker demand recovery in China. The property sector in China remains sluggish, with declining new home prices. Inflationary pressures are impacting consumer durables and building and construction demand. Demand in infrastructure, including residential construction, also remains weak. Dow sees softness in automotive in Europe due to low demand. Soft conditions across these markets are likely to have weighed on DOW's volumes in the second quarter. Weak macroeconomic conditions due to disruptions caused by tariffs are expected to have affected business and consumer sentiment. Dow is also being challenged by weak siloxane prices in its Performance Materials & Coatings unit. The segment continues to see siloxane pricing pressure partly due to supply additions in Asia. Siloxane prices remain under pressure due to competitive pricing pressure resulting from additional supply driven by capacity additions in China. While capacity additions have slowed, elevated industry supply is expected to continue to have impacted prices in the second quarter. Nevertheless, Dow is likely to have benefited from cost-saving and productivity actions. DOW is implementing targeted actions focused on reducing direct costs and labor costs. It is taking action to cut costs by $1 billion to drive margins. Dow sees around $300 million in benefits from these actions in 2025, with full benefits expected by 2026. The benefits of DOW's cost-saving actions are likely to be reflected in its bottom line in the to-be-reported quarter. Dow Inc. Price and EPS Surprise Dow Inc. price-eps-surprise | Dow Inc. Quote What Our Model Unveils for DOW Stock Our proven model does not conclusively predict an earnings beat for DOW this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that's not the case here. Earnings ESP: Earnings ESP for DOW is -53.04%. The Zacks Consensus Estimate for the second quarter is currently pegged at a loss of 8 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: DOW currently carries a Zacks Rank #5 (Strong Sell). Basic Materials Stocks That Warrant a Look Here are some companies in the basic materials space you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Agnico Eagle Mines Limited AEM, scheduled to release earnings on July 30, has an Earnings ESP of +8.77% and carries a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. The consensus estimate for AEM's earnings for the second quarter is currently pegged at $1.66. Newmont Corporation NEM, slated to release earnings on July 24, has an Earnings ESP of +4.42% and carries a Zacks Rank #2 at present. The consensus mark for NEM's second-quarter earnings is currently pegged at $1.05. Kinross Gold Corporation KGC, scheduled to release earnings on July 30, has an Earnings ESP of +15.34%. The Zacks Consensus Estimate for KGC's earnings for the second quarter is currently pegged at 27 cents. KGC currently carries a Zacks Rank #1. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dow Inc. (DOW): Free Stock Analysis Report Newmont Corporation (NEM): Free Stock Analysis Report Kinross Gold Corporation (KGC): Free Stock Analysis Report Agnico Eagle Mines Limited (AEM): Free Stock Analysis Report


Globe and Mail
an hour ago
- Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern's RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern's strategic partnership potential. To view the full press release, visit About Lantern Pharma Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program. NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: